Indications for LEXETTE:
≥18yrs: Apply a thin layer to affected areas twice daily for up to 2 weeks; max 50g/week. Discontinue when control is achieved. Reevaluate if no improvement within 2 weeks. Treatment beyond 2 consecutive weeks: not recommended. Do not occlude.
<18yrs: not established.
Not for ophthalmic, oral, or intravaginal use. Avoid use near eyes, on face, groin, or axillae. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, occlusive use, altered skin barrier, concomitant multiple corticosteroid-containing products, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Increased risk of posterior subcapsular cataracts and glaucoma. Treat infection if present or develop; discontinue until infection resolved. Discontinue if allergic contact dermatitis occurs. Flammable. Reevaluate periodically. Pregnancy. Nursing mothers: avoid direct infant exposure.
Application site pain, headache, local adverse reactions (eg, atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, dermatitis, secondary infection, miliaria); Cushing's syndrome, glucosuria, HPA axis suppression (esp. in children).